Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01652976 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma
A Phase 2 study of Pancreatic Cancer Metastatic, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT01652976 is a Phase 2 study of Pancreatic Cancer Metastatic that has completed, run by University of Florida. The registered enrollment target is 44 participants, below the 127-participant average among 9 other Pancreatic Cancer Metastatic trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01652976, a Phase 2 study of Pancreatic Cancer Metastatic, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine if the study drug, dasatinib, given in combination with 5-Fluorouracil, leucovorin and oxaliplatin (FOLFOX) will work against metastatic pancreatic cancer. Dasatinib is a Food and Drug Administration (FDA) approved drug for treating chronic myelogenous leukemia and acute lymphoblastic leukemia, however it is not currently approved for use in the treatment of pancreatic cancer.
Conditions Studied
Interventions
- DRUG Dasatinib
- DRUG mFOLFOX6
Study Locations (1)
Florida
- UF Health Cancer Center - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2012-07 |
| Est. Completion | 2020-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01652976
The ClinicalTrials.gov registry entry for NCT01652976 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 127-participant average among 9 other Pancreatic Cancer Metastatic trials with a reported enrollment target (65% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer Metastatic appearing as the primary indexed condition, and to 2 interventions - of which Dasatinib is the first listed.
NCT01652976 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT01652976 about?
NCT01652976 is a clinical study titled "Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma". The purpose of this research study is to determine if the study drug, dasatinib, given in combination with 5-Fluorouracil, leucovorin and oxaliplatin (FOLFOX) will work against metastatic pancreatic cancer. Dasatinib is a Food and Drug Administration (FDA) approved drug for treating chronic myeloge...
What is the current status of trial NCT01652976?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2012-07. Estimated completion is 2020-07.
What conditions does trial NCT01652976 study?
This clinical trial studies the following conditions: Pancreatic Cancer Metastatic.
What interventions are being tested in trial NCT01652976?
The interventions under investigation include: Dasatinib (DRUG), mFOLFOX6 (DRUG).
Who is sponsoring clinical trial NCT01652976?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01652976 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
RECRUITING · Phase 2
-
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
RECRUITING · Phase 2
-
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
COMPLETED · Phase 2
-
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
RECRUITING · Phase 1
-
A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.